>
pdufa.bio

nimacimab

Updated ยทnext FDA decision on the calendar

nimacimab is a Skye Bioscience, Inc. program. Its next catalyst is a Readout in Q4 2026. Every date links its source.

SKYE catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Skye Bioscience, Inc. (SKYE). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2026SKYE

Questions

When is nimacimab's next FDA decision or readout?

The next tracked catalyst for nimacimab is a Readout in Q4 2026.

What happened at nimacimab's most recent FDA decision?

No FDA decision for nimacimab is in our archive yet.

Who makes nimacimab?

Skye Bioscience, Inc. (SKYE).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.